TY - JOUR
T1 - 2019 Diagnostic criteria for mixed connective tissue disease (MCTD)
T2 - From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases
AU - Tanaka, Yoshiya
AU - Kuwana, Masataka
AU - Fujii, Takao
AU - Kameda, Hideto
AU - Muro, Yoshinao
AU - Fujio, Keishi
AU - Itoh, Yasuhiko
AU - Yasuoka, Hidekata
AU - Fukaya, Shusaku
AU - Ashihara, Konomi
AU - Hirano, Daisuke
AU - Ohmura, Koichiro
AU - Tabuchi, Yuya
AU - Hasegawa, Hisanori
AU - Matsumiya, Ryo
AU - Shirai, Yuichiro
AU - Ogura, Takehisa
AU - Tsuchida, Yumi
AU - Ogawa-Momohara, Mariko
AU - Narazaki, Hidehiko
AU - Inoue, Yoshino
AU - Miyagawa, Ippei
AU - Nakano, Kazuhisa
AU - Hirata, Shintaro
AU - Mori, Masaaki
N1 - Funding Information:
The authors wish to thank all the patients for their contribution to the study. The authors thank all medical staff in all institutions for providing the data. This work was supported in part by a Grant-In-Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan.
Funding Information:
Yoshiya Tanaka has received speaking fees and/or honoraria from Daiichi-Sankyo, Astellas, Chugai, Eli Lilly, Pfizer, Abbvie, YL Biologics, Bristol-Myers, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, Teijin and has received research grants from Asahi-kasei, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers, UCB, Daiichi-Sankyo, Eisai and Ono. Masataka Kuwana has received speaking fees and/or honoraria from Abbvie, Actelion, Astellas, Ayumi, Bayer, Boehringer-ingelheim, Chugai, Eisai, Janssen, GSK, Mitsubishi Tanabe, Novartis, Ono, Pfizer, Nippon Shinyaku, and Takeda, and has received research grants from Actelion, Asahi-kasei, Mitsubishi-Tanabe, Chugai, Eisai, Nippon-Kayaku, and Ono. Takao Fujii has received speaking fees and/or honoraria from Abbvie, Astellas, Asahi-kasei, Chugai, Eli Lilly, Eisai, Janssen, Kissei, Mitsubishi-Tanabe, Ono, Pfizer, Sanofi, Taisho Toyama, Takeda, and UCB, and has received research grants from AbbVie, Ayumi, Asahi-kasei, Astellas, Chugai, Daiichi-Sankyo, Eli Lilly, Eisai, Kissei, Mitsubishi-Tanabe, Pfizer, Nippon-Kayaku, Ono, Takeda, and UCB. Hideto Kameda has received speaking fees and/or honoraria from AbbVie GK, Asahi-Kasei, Astellas, Bristol-Myers, Chugai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Novartis and Pfizer, and has received research grants from AbbVie GK, Asahi-Kasei, Astellas, Chugai, Eisai, Mitsubishi-Tanabe and Novartis. Keishi Fujio has received speaking fees and/or honoraria from Tanabe Mitsubishi, Bristol Myers, Eli Lilly, Chugai, Jansen, Pfizer, Ono, Abbie, Ayumi, Astellas, Sanofi, Novartis, Daiichi Sankyo, Eisai, Asahi Kasei, Japan Blood Products Organization, and Kowa, and has received research grants from Tanabe Mitsubishi, Bristol Myers, Eli Lilly, Chugai, Abbie, Ayumi, Astellas, Sanofi, Eisai, and Asahi Kasei. Koichiro Ohmura has received speaking fees and/or honoraria from Abbvie, Actelion, Astellas, Ayumi, Asahikasei-Pharma, Bristol-Myers, Eisai, Eli Lilly, GSK, Janssen, Mitsubishi Tanabe, Novartis, Sanofi and has received research grants from Bristol-Myers, Eisai, Eli Lilly, GSK, Mitsubishi-Tanabe, Nippon-Kayaku. Hisanori Hasegawa has received speaking fees and/or honoraria from Astellas, Chugai, Eli Lilly, Pfizer, Bristol-Myers, Eisai, Janssen, Teijin, Asahi-kasei, Nihon Pharmaceutical, Ono and has received research grants from Mitsubishi-Tanabe. Yuichiro Shirai has received a research grant from Actelion. Shintaro Hirata has received consultancy fee, advisory fee, or speaker bureau from AbbVie, Asahi-Kasei Pharma, Asahi-Kasei Medical, Astellas, Ayumi, Bristol-Myers Squibb, Celgene, Chugai, Eisai, Eli Lilly, Janssen, Kissei, Novartis, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. Tokyo Medical and Dental University received unrestricted research grants for Department of Lifetime Clinical Immunology from AbbVie, Ayumi, Chugai, CSL Behring, Japan Blood Products Organization, Nippon Kayaku, UCB Japan, Asahi-Kasei. Others do not have conflict of interests.
PY - 2021
Y1 - 2021
N2 - Objective: To update and revise the diagnostic criteria for mixed connective tissue disease (MCTD) issued by the Japan Research Committee of the Ministry of Health, Labor, and Welfare (MHLW), a round table discussion by experts from rheumatology, dermatology, and pediatric medicine was conducted in multiple occasions. Methods: The definition of MCTD, and items included in the diagnostic criteria were generated by consensus method and evaluation using clinical data of typical and borderline cases of MCTD, by applying to the diagnostic criteria for MCTD proposed in 1996 and 2004 by the Research Committee of MHLW. Results: To the end, all committee members reached consensus. Then, the criteria were assessed in an independent validation cohort and tested against preexisting criteria. The revised criteria facilitate an understanding of the overall picture of this disease by describing the concept of MCTD, common manifestations, immunological manifestation and characteristic organ involvement. Conditions with characteristic organ involvement include pulmonary arterial hypertension, aseptic meningitis and trigeminal neuropathy. Even if the overlapping manifestations are absent, MCTD can be diagnosed based on the presence of the characteristic organ involvement. Furthermore, the criteria were validated for applicability in actual clinical cases, and public comments were solicited from the Japan College of Rheumatology and other associated societies. Conclusion: After being reviewed through public comments, the revised diagnostic criteria have been finalized.
AB - Objective: To update and revise the diagnostic criteria for mixed connective tissue disease (MCTD) issued by the Japan Research Committee of the Ministry of Health, Labor, and Welfare (MHLW), a round table discussion by experts from rheumatology, dermatology, and pediatric medicine was conducted in multiple occasions. Methods: The definition of MCTD, and items included in the diagnostic criteria were generated by consensus method and evaluation using clinical data of typical and borderline cases of MCTD, by applying to the diagnostic criteria for MCTD proposed in 1996 and 2004 by the Research Committee of MHLW. Results: To the end, all committee members reached consensus. Then, the criteria were assessed in an independent validation cohort and tested against preexisting criteria. The revised criteria facilitate an understanding of the overall picture of this disease by describing the concept of MCTD, common manifestations, immunological manifestation and characteristic organ involvement. Conditions with characteristic organ involvement include pulmonary arterial hypertension, aseptic meningitis and trigeminal neuropathy. Even if the overlapping manifestations are absent, MCTD can be diagnosed based on the presence of the characteristic organ involvement. Furthermore, the criteria were validated for applicability in actual clinical cases, and public comments were solicited from the Japan College of Rheumatology and other associated societies. Conclusion: After being reviewed through public comments, the revised diagnostic criteria have been finalized.
UR - http://www.scopus.com/inward/record.url?scp=85078602781&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078602781&partnerID=8YFLogxK
U2 - 10.1080/14397595.2019.1709944
DO - 10.1080/14397595.2019.1709944
M3 - Article
C2 - 31903831
AN - SCOPUS:85078602781
VL - 31
SP - 29
EP - 33
JO - Modern Rheumatology
JF - Modern Rheumatology
SN - 1439-7595
IS - 1
ER -